News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,920 Results
Type
Article (8045)
Company Profile (140)
Press Release (477638)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166758)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52888)
Employer Resources (14)
FDA (9761)
Job Trends (8576)
News (238218)
Policy (17900)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (489)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33160)
ALS (107)
Alzheimer's disease (985)
Antibody-drug conjugate (ADC) (281)
Approvals (10402)
Artificial intelligence (328)
ASCO (159)
Autoimmune disease (219)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (30)
Breast cancer (517)
Cancer (3739)
Cardiovascular disease (225)
Career advice (246)
Career pathing (1)
CAR-T (177)
CDMO (14)
Celiac Disease (1)
Cell therapy (485)
Cervical cancer (35)
Clinical research (48016)
Collaboration (1273)
Commercialization (3)
Compensation (1524)
Complete response letters (34)
COVID-19 (760)
CRISPR (64)
C-suite (796)
Cystic fibrosis (87)
Data (5825)
Denatured (4)
Depression (104)
Dermatology (67)
Diabetes (351)
Diagnostics (4205)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73749)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88065)
Executive appointments (711)
FDA (12465)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (937)
Gene editing (126)
Generative AI (9)
Gene therapy (329)
GLP-1 (295)
Government (947)
Grass and pollen (2)
Guidances (281)
Healthcare (9368)
Hematology (95)
HIV (53)
Huntington's disease (22)
IgA nephropathy (66)
Immunology and inflammation (103)
Immuno-oncology (61)
Indications (159)
Infectious disease (951)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (259)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (236)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5196)
Licensing (17)
Liver cancer (45)
Longevity (19)
Lung cancer (529)
Lymphoma (257)
Machine learning (27)
Management (3)
Manufacturing (558)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8676)
Medtech (8831)
Mergers & acquisitions (14405)
Metabolic disorders (723)
mRNA (60)
Multiple sclerosis (108)
NASH (4)
Neurodegenerative disease (224)
Neuropsychiatric disorders (40)
Neuroscience (1858)
NextGen: Class of 2026 (3151)
Non-profit (843)
Now hiring (4)
Obesity (231)
Opinion (11)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (204)
Partnered (12)
Patents (492)
Patient recruitment (526)
Patient selection (1)
Peanut (32)
People (41337)
Peptides (1)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15516)
Phase 2 (21442)
Phase 3 (14459)
Pipeline (7632)
Policy (18)
Postmarket research (1570)
Preclinical (6551)
Press Release (34)
Prostate cancer (194)
Psychedelics (7)
Radiopharmaceuticals (194)
Rare diseases (586)
Real estate (3022)
Recruiting (6)
Regenerative medicine (1)
Regulatory (14925)
Reports (23)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (158)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2023)
Stomach cancer (3)
Supply chain (51)
Vaccines (332)
Venture capital (17)
Weight loss (74)
Women's health (85)
Date
Today (66)
Last 7 days (435)
Last 30 days (1353)
Last 365 days (19086)
2026 (13435)
2025 (19256)
2024 (22986)
2023 (26544)
2022 (34599)
2021 (37172)
2020 (33471)
2019 (23277)
2018 (17494)
2017 (18766)
2016 (17920)
2015 (24268)
2014 (21685)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (231)
Alabama (77)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (17955)
Australia (2108)
California (12298)
Canada (3220)
China (543)
Colorado (493)
Connecticut (425)
Delaware (211)
Europe (24701)
Florida (1844)
Georgia (392)
Hawaii (3)
Idaho (46)
Illinois (724)
India (52)
Indiana (321)
Iowa (16)
Japan (418)
Kansas (102)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1227)
Massachusetts (8071)
Michigan (312)
Minnesota (569)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (120)
New Hampshire (60)
New Jersey (2682)
New Mexico (12)
New York (2882)
North Carolina (1312)
North Dakota (4)
Northern California (6179)
Ohio (291)
Oklahoma (14)
Oregon (18)
Pennsylvania (2290)
Puerto Rico (21)
Rhode Island (30)
South America (408)
South Carolina (77)
South Dakota (1)
Southern California (5116)
Tennessee (123)
Texas (1993)
United States (39863)
Utah (367)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,920 Results for "nurix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader
Roche and Nurix Therapeutics will advance their BTK degrader for chronic lymphocytic leukemia, as well as immunology and neurology indications.
June 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Nurix Therapeutics to Participate in Upcoming September 2026 Investor Conferences
September 1, 2026
·
4 min read
Press Releases
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
August 20, 2026
·
5 min read
Press Releases
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 10, 2026
·
16 min read
Press Releases
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
August 4, 2026
·
7 min read
Press Releases
Nurix Therapeutics to Participate in Upcoming Investor Conferences - May 13, 2026
May 13, 2026
·
2 min read
Press Releases
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
May 13, 2026
·
3 min read
Press Releases
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
August 4, 2026
·
7 min read
Press Releases
Nurix Therapeutics to Participate in Upcoming April 2026 Investor Conference
April 7, 2026
·
2 min read
Press Releases
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
July 22, 2026
·
7 min read
1 of 48,592
Next
